» Articles » PMID: 9933644

The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor-beta1, Fibronectin, and Plasminogen Activator Inhibitor-1

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1999 Feb 6
PMID 9933644
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Re-expression of EGR-1 in fibrosarcoma HT1080 suppresses transformation including tumorigenicity (Huang, R.-P., Liu, C., Fan, Y., Mercola, D., and Adamson, E. (1995) Cancer Res. 55, 5054-5062) owing in part to up-regulation of the transforming growth factor (TGF)-beta1 promoter by EGR-1 which suppresses growth by an autocrine mechanism (Liu, C., Adamson, E., and Mercola, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11831-11836). Here we show that enhanced cell attachment contributes to the suppression via increased secretion of fibronectin (FN) and also of plasminogen activator inhibitor-1 (PAI-1). The secretion of FN and PAI-1 is strongly correlated with EGR-1 expression (RPEARSON = 0.971 and 0. 985, respectively). Addition of authentic TGF-beta1 to parental cells greatly stimulated secretion of PAI-1 but not FN, whereas addition of TGF-beta antibody or lipofection with specific antisense TGF-beta1 oligonucleotides to EGR-1-regulated cells completely inhibits the secretion of PAI-1 but not FN. However, in gel mobility shift assays pure EGR-1 or nuclear extracts of EGR-1-regulated cells specifically bind to two GC-rich elements of the human FN promoter at positions -75/-52 and -4/+18, indicating that the increased secretion of FN is likely due to direct up-regulation by EGR-1. Moreover, adhesion was greatly enhanced in EGR-1-regulated cells and was reversed by treatment with Arg-Gly-Asp (RGD) or PAI-1 antibody indicating that the secreted proteins are functional. We conclude that EGR-1 regulates the coordinated expression of gene products important for cell attachment ("oikis" factor) and normal growth control.

Citing Articles

Host signaling and EGR1 transcriptional control of human cytomegalovirus replication and latency.

Buehler J, Carpenter E, Zeltzer S, Igarashi S, Rak M, Mikell I PLoS Pathog. 2019; 15(11):e1008037.

PMID: 31725811 PMC: 6855412. DOI: 10.1371/journal.ppat.1008037.


HCMV miR-US22 down-regulation of EGR-1 regulates CD34+ hematopoietic progenitor cell proliferation and viral reactivation.

Mikell I, Crawford L, Hancock M, Mitchell J, Buehler J, Goodrum F PLoS Pathog. 2019; 15(11):e1007854.

PMID: 31725809 PMC: 6855405. DOI: 10.1371/journal.ppat.1007854.


Identification, Characterization, and Regulatory Mechanisms of a Novel EGR1 Splicing Isoform.

Aliperti V, Sgueglia G, Aniello F, Vitale E, Fucci L, Donizetti A Int J Mol Sci. 2019; 20(7).

PMID: 30925677 PMC: 6479754. DOI: 10.3390/ijms20071548.


Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1.

Szatmari T, Mundt F, Kumar-Singh A, Mobus L, Otvos R, Hjerpe A BMC Cell Biol. 2017; 18(1):34.

PMID: 29216821 PMC: 5721467. DOI: 10.1186/s12860-017-0150-z.


CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A.

Tu Q, Hao J, Zhou X, Yan L, Dai H, Sun B Oncogene. 2017; 37(1):128-138.

PMID: 28892048 PMC: 5759028. DOI: 10.1038/onc.2017.316.